Eli Lilly Announces $27 Billion Investment in U.S. Manufacturing Expansion

The pharmaceutical giant plans to build four new plants, creating thousands of jobs, as Trump administration tariffs loom over drug imports.

Eli Lilly will invest $27 billion to construct four new pharmaceutical manufacturing plants in the U.S., focusing on active pharmaceutical ingredients and injectable medicines.
The new facilities are expected to create over 3,000 high-skilled jobs and 10,000 construction jobs, with locations to be announced later this year.
This investment raises Eli Lilly's total U.S. manufacturing commitments to $50 billion since 2020, supported in part by the 2017 corporate tax cuts.
The announcement follows President Trump's push for reshoring manufacturing, including a proposed 25% tariff on pharmaceutical imports.
The company aims to bolster domestic supply chains, reduce reliance on foreign suppliers, and meet growing demand for blockbuster drugs like Zepbound and Mounjaro.